Artia Global Partners LP Takes Position in Alumis Inc. $ALMS

Artia Global Partners LP purchased a new position in Alumis Inc. (NASDAQ:ALMS - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 278,546 shares of the company's stock, valued at approximately $7,838,000. Alumis accounts for about 1.4% of Artia Global Partners LP's investment portfolio, making the stock its 15th biggest position. Artia Global Partners LP owned approximately 0.22% of Alumis at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. KBC Group NV purchased a new position in Alumis in the 1st quarter valued at approximately $42,000. Strs Ohio lifted its holdings in shares of Alumis by 300.0% during the 1st quarter. Strs Ohio now owns 2,000 shares of the company's stock worth $44,000 after acquiring an additional 1,500 shares during the last quarter. State of Wyoming purchased a new position in Alumis in the first quarter worth $57,000. EverSource Wealth Advisors LLC grew its position in Alumis by 600.4% in the first quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company's stock worth $69,000 after acquiring an additional 2,684 shares in the last quarter. Finally, Assetmark Inc. bought a new position in Alumis in the first quarter valued at $92,000.

Alumis Stock Performance

Shares of ALMS stock opened at $23.62 on Thursday. Alumis Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $31.35. The stock has a 50 day moving average price of $26.58 and a two-hundred day moving average price of $25.13. The company has a market capitalization of $3.06 billion, a P/E ratio of -6.12 and a beta of -0.69.

Alumis (NASDAQ:ALMS - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The firm had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. As a group, equities analysts predict that Alumis Inc. will post -2.95 earnings per share for the current year.

Insider Transactions at Alumis

In other news, insider Roy C. Hardiman sold 2,692 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $70,988.04. Following the completion of the transaction, the insider directly owned 207,746 shares of the company's stock, valued at approximately $5,478,262.02. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark Christopher Bradley sold 2,572 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $67,823.64. Following the sale, the insider owned 48,533 shares of the company's stock, valued at approximately $1,279,815.21. This represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 19,953 shares of company stock valued at $534,311. Company insiders own 33.70% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wall Street Zen upgraded Alumis from a "strong sell" rating to a "hold" rating in a report on Sunday. Weiss Ratings restated a "sell (d-)" rating on shares of Alumis in a research report on Tuesday, July 7th. HC Wainwright reaffirmed a "neutral" rating and issued a $25.00 target price on shares of Alumis in a research note on Friday, August 14th. Chardan Capital increased their price target on shares of Alumis from $38.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, May 19th. Finally, Wells Fargo & Company lifted their price target on shares of Alumis from $49.00 to $51.00 and gave the stock an "overweight" rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $40.30.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source